Cargando…

Exploration of the threshold SUV for diagnosis of malignancy using (18)F-FBPA PET/CT

BACKGROUND: The goal of the study was to evaluate the diagnostic ability of (18)F-FBPA PET/CT for malignant tumors. Findings from (18)F-FBPA and (18)F-FDG PET/CT were compared with pathological diagnoses in patients with malignant tumors or benign lesions. METHODS: A total of 82 patients (45 males,...

Descripción completa

Detalles Bibliográficos
Autores principales: Isohashi, Kayako, Kanai, Yasukazu, Aihara, Teruhito, Hu, Naonori, Fukushima, Kentaro, Baba, Ichiro, Hirokawa, Fumitoshi, Kakino, Ryo, Komori, Tsuyoshi, Nihei, Keiji, Hatazawa, Jun, Ono, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719878/
https://www.ncbi.nlm.nih.gov/pubmed/36464732
http://dx.doi.org/10.1186/s41824-022-00156-z
_version_ 1784843423378833408
author Isohashi, Kayako
Kanai, Yasukazu
Aihara, Teruhito
Hu, Naonori
Fukushima, Kentaro
Baba, Ichiro
Hirokawa, Fumitoshi
Kakino, Ryo
Komori, Tsuyoshi
Nihei, Keiji
Hatazawa, Jun
Ono, Koji
author_facet Isohashi, Kayako
Kanai, Yasukazu
Aihara, Teruhito
Hu, Naonori
Fukushima, Kentaro
Baba, Ichiro
Hirokawa, Fumitoshi
Kakino, Ryo
Komori, Tsuyoshi
Nihei, Keiji
Hatazawa, Jun
Ono, Koji
author_sort Isohashi, Kayako
collection PubMed
description BACKGROUND: The goal of the study was to evaluate the diagnostic ability of (18)F-FBPA PET/CT for malignant tumors. Findings from (18)F-FBPA and (18)F-FDG PET/CT were compared with pathological diagnoses in patients with malignant tumors or benign lesions. METHODS: A total of 82 patients (45 males, 37 females; median age, 63 years; age range, 20–89 years) with various types of malignant tumors or benign lesions, such as inflammation and granulomas, were examined by (18)F-FDG and (18)F-FBPA PET/CT. Tumor uptake of FDG or FBPA was quantified using the maximum standardized uptake value (SUVmax). The final diagnosis was confirmed by cytopathology or histopathological findings of the specimen after biopsy or surgery. A ROC curve was constructed from the SUVmax values of each PET image, and the area under the curve (AUC) and cutoff values were calculated. RESULTS: The SUVmax for (18)F-FDG PET/CT did not differ significantly for malignant tumors and benign lesions (10.9 ± 6.3 vs. 9.1 ± 2.7 P = 0.62), whereas SUVmax for (18)F-FBPA PET/CT was significantly higher for malignant tumors (5.1 ± 3.0 vs. 2.9 ± 0.6, P < 0.001). The best SUVmax cutoffs for distinguishing malignant tumors from benign lesions were 11.16 for (18)F-FDG PET/CT (sensitivity 0.909, specificity 0.390) and 3.24 for (18)F-FBPA PET/CT (sensitivity 0.818, specificity 0.753). ROC analysis showed significantly different AUC values for (18)F-FDG and (18)F-FBPA PET/CT (0.547 vs. 0.834, p < 0.001). CONCLUSION: (18)F-FBPA PET/CT showed superior diagnostic ability over (18)F-FDG PET/CT in differential diagnosis of malignant tumors and benign lesions. The results of this study suggest that (18)F-FBPA PET/CT diagnosis may reduce false-positive (18)F-FDG PET/CT diagnoses.
format Online
Article
Text
id pubmed-9719878
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-97198782022-12-06 Exploration of the threshold SUV for diagnosis of malignancy using (18)F-FBPA PET/CT Isohashi, Kayako Kanai, Yasukazu Aihara, Teruhito Hu, Naonori Fukushima, Kentaro Baba, Ichiro Hirokawa, Fumitoshi Kakino, Ryo Komori, Tsuyoshi Nihei, Keiji Hatazawa, Jun Ono, Koji Eur J Hybrid Imaging Original Article BACKGROUND: The goal of the study was to evaluate the diagnostic ability of (18)F-FBPA PET/CT for malignant tumors. Findings from (18)F-FBPA and (18)F-FDG PET/CT were compared with pathological diagnoses in patients with malignant tumors or benign lesions. METHODS: A total of 82 patients (45 males, 37 females; median age, 63 years; age range, 20–89 years) with various types of malignant tumors or benign lesions, such as inflammation and granulomas, were examined by (18)F-FDG and (18)F-FBPA PET/CT. Tumor uptake of FDG or FBPA was quantified using the maximum standardized uptake value (SUVmax). The final diagnosis was confirmed by cytopathology or histopathological findings of the specimen after biopsy or surgery. A ROC curve was constructed from the SUVmax values of each PET image, and the area under the curve (AUC) and cutoff values were calculated. RESULTS: The SUVmax for (18)F-FDG PET/CT did not differ significantly for malignant tumors and benign lesions (10.9 ± 6.3 vs. 9.1 ± 2.7 P = 0.62), whereas SUVmax for (18)F-FBPA PET/CT was significantly higher for malignant tumors (5.1 ± 3.0 vs. 2.9 ± 0.6, P < 0.001). The best SUVmax cutoffs for distinguishing malignant tumors from benign lesions were 11.16 for (18)F-FDG PET/CT (sensitivity 0.909, specificity 0.390) and 3.24 for (18)F-FBPA PET/CT (sensitivity 0.818, specificity 0.753). ROC analysis showed significantly different AUC values for (18)F-FDG and (18)F-FBPA PET/CT (0.547 vs. 0.834, p < 0.001). CONCLUSION: (18)F-FBPA PET/CT showed superior diagnostic ability over (18)F-FDG PET/CT in differential diagnosis of malignant tumors and benign lesions. The results of this study suggest that (18)F-FBPA PET/CT diagnosis may reduce false-positive (18)F-FDG PET/CT diagnoses. Springer International Publishing 2022-12-05 /pmc/articles/PMC9719878/ /pubmed/36464732 http://dx.doi.org/10.1186/s41824-022-00156-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Isohashi, Kayako
Kanai, Yasukazu
Aihara, Teruhito
Hu, Naonori
Fukushima, Kentaro
Baba, Ichiro
Hirokawa, Fumitoshi
Kakino, Ryo
Komori, Tsuyoshi
Nihei, Keiji
Hatazawa, Jun
Ono, Koji
Exploration of the threshold SUV for diagnosis of malignancy using (18)F-FBPA PET/CT
title Exploration of the threshold SUV for diagnosis of malignancy using (18)F-FBPA PET/CT
title_full Exploration of the threshold SUV for diagnosis of malignancy using (18)F-FBPA PET/CT
title_fullStr Exploration of the threshold SUV for diagnosis of malignancy using (18)F-FBPA PET/CT
title_full_unstemmed Exploration of the threshold SUV for diagnosis of malignancy using (18)F-FBPA PET/CT
title_short Exploration of the threshold SUV for diagnosis of malignancy using (18)F-FBPA PET/CT
title_sort exploration of the threshold suv for diagnosis of malignancy using (18)f-fbpa pet/ct
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719878/
https://www.ncbi.nlm.nih.gov/pubmed/36464732
http://dx.doi.org/10.1186/s41824-022-00156-z
work_keys_str_mv AT isohashikayako explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT kanaiyasukazu explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT aiharateruhito explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT hunaonori explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT fukushimakentaro explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT babaichiro explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT hirokawafumitoshi explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT kakinoryo explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT komoritsuyoshi explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT niheikeiji explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT hatazawajun explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct
AT onokoji explorationofthethresholdsuvfordiagnosisofmalignancyusing18ffbpapetct